RealClearHealth - Opinion, News, Analysis, Video and Polls

Monday, March 18

Set this view as default? Yes No

Set this view as default? Yes No

There Will Never Be COVID Accountability

Vinay Prasad, Observations and Thoughts

How the World Has Radically Cut Child Deaths

Dylan Scott, Vox

White House Wants to Double Dip on Drug Rebates

Tomas Philipson, RealClearHealth

Attacking PBMs Won’t Solve Inflation Problem

Pat Toomey, RealClearHealth

Drug Price Shenanigans

Grace-Marie Turner, RealClearHealth

Medicare Is Now Unaffordable

Sally Pipes, Newsmax

Private Equity Is the Partner Health Care Needs

Drew Maloney, RealClearHealth

Medicare’s Price-Setting Rules

Capretta, Bernstein, & Rowing, Health Affairs

A Solution in Search of a Problem

Joel Zinberg, City Journal

5 Takeaways From Politico’s Healthcare Summit

Carmen Paun & Daniel Payne, Politico

Sign up for our free morning newsletter: Daily Newsletters | RealClearHealth

Research & Analysis

Quality Outcomes: Medicare Advantage vs. Fee-for-Service

Vabson, et al., AEI

Courting Healthcare Reimbursement Ambiguity

Peter Pitts, DrugWonks

Govt Investment Into Vaccines Hasn't Paid Off

D. Livermore, Brownstone Institute

First Amendment, Social Media, & 'Anti-Vax-Misinformation'

Billauer & Milller, ACSH

Reimagining Healthcare

Sponsored Curation Powered By:

Essential Reading

Misguided March-In: The Perilous Proposal to Police Drug Prices and Its Threat to American Innovation

The National Institute of Standards and Technology's (NIST) recent proposal to wield the "March-In Rights" under the 1980 Bayh-Dole Act as a tool for price-fixing drugs has ignited a firestorm of debate among stakeholders in the pharmaceutical, legal, and policy-making communities. At its core, this proposal seeks to expand the scope of “March-In Rights”—originally designed to ensure public access to inventions arising from federally funded research—to include considerations of the pricing of pharmaceutical products.

Price-fixing Racket Sacrifices New Meds for Senior Americans

The Inflation Reduction Act is threatening research and development for medications urgently needed to meet complex health challenges American seniors are enduring.

Multimedia

How Twitter Harmed Science

Lockdowns Brought Us Back to the Dark Ages, Can We Come Back From It?

Full Replay: President Biden Delivers Update On COVID-19 Response, Vaccinations

More From Real Clear

Videos

The Value, Science, & Policies Surrounding Vaccines

What Doesn't Kill You ...

Was Trump's Operation Warp Speed a Success?

A Personal Option for Health Care | Health Care Reimagined | Americans for Prosperity

There Will Never Be COVID Accountability

Vinay Prasad, Observations and Thoughts

Rochelle Walensky was CDC director under Biden, and in that capacity made mistakes. Read More

How the World Has Radically Cut Child Deaths

Dylan Scott, Vox

Fewer kids are dying than ever before — but a lot of work remains. Read More

White House Wants to Double Dip on Drug Rebates

Tomas Philipson, RealClearHealth

As part of its "Strike Force on Unfair and Illegal Pricing," the White House just doubled down on a December plan to allow the federal... Read More

Attacking PBMs Won’t Solve Inflation Problem

Pat Toomey, RealClearHealth

What is a president to do when, after insisting on trillions of dollars of excessive, wasteful spending, the resulting record-setting... Read More

Drug Price Shenanigans

Grace-Marie Turner, RealClearHealth

President Biden’s State of the Union address highlighted a long list of “health care” proposals he’s planning in a... Read More

Medicare Is Now Unaffordable

Sally Pipes, Newsmax

"If anyone here tries to cut ... Medicare ... I will stop you." That was President Biden's promise to a joint... Read More

Private Equity Is the Partner Health Care Needs

Drew Maloney, RealClearHealth

Anyone who's gone to the emergency room or had to fill a prescription for medication knows firsthand that America's healthcare system is one... Read More

Medicare’s Price-Setting Rules

Capretta, Bernstein, & Rowing, Health Affairs

The growing financial burden from high commercial prices for medical services is fueling calls for reform. Read More

A Solution in Search of a Problem

Joel Zinberg, City Journal

President Biden’s promise to expand drug-price controls will imperil supply and innovation. Read More

5 Takeaways From Politico’s Healthcare Summit

Carmen Paun & Daniel Payne, Politico

Top Biden administration officials went on the offensive at POLITICO’s 2024 Health Care Summit Wednesday in Washington, laying out the... Read More

Research & Analysis

Quality Outcomes: Medicare Advantage vs. Fee-for-Service

Vabson, et al., AEI

While Medicare Advantage (MA) now covers over half of Medicare beneficiaries, including a disproportionate share of those facing... Read More

Courting Healthcare Reimbursement Ambiguity

Peter Pitts, DrugWonks

Default Description | Drugwonks.com is the web log of the Center for Medicine in the Public Interest (CMPI), a forum offering rigorous and... Read More

Govt Investment Into Vaccines Hasn't Paid Off

D. Livermore, Brownstone Institute

Unless and until manufactures can show that, with the right payload, mRNA vaccines are as safe and effective as traditional vaccines against... Read More

First Amendment, Social Media, & 'Anti-Vax-Misinformation'

Billauer & Milller, ACSH

In March, the U.S. Supreme Court will determine the extent of permissible federal interactions with private-party decision-making – namely,... Read More

Reimagining Healthcare

Sponsored Curation Powered By:

Essential Reading

Misguided March-In: The Perilous Proposal to Police Drug Prices and Its Threat to American Innovation

The National Institute of Standards and Technology's (NIST) recent proposal to wield the "March-In Rights" under the 1980 Bayh-Dole Act as a tool for price-fixing drugs has ignited a firestorm of debate among stakeholders in the pharmaceutical, legal, and policy-making communities. At its core, this proposal seeks to expand the scope of “March-In Rights”—originally designed to ensure public access to inventions arising from federally funded research—to include considerations of the pricing of pharmaceutical products.

Price-fixing Racket Sacrifices New Meds for Senior Americans

The Inflation Reduction Act is threatening research and development for medications urgently needed to meet complex health challenges American seniors are enduring.

Multimedia

How Twitter Harmed Science

Lockdowns Brought Us Back to the Dark Ages, Can We Come Back From It?

Full Replay: President Biden Delivers Update On COVID-19 Response, Vaccinations

More From Real Clear

Videos

The Value, Science, & Policies Surrounding Vaccines

What Doesn't Kill You ...

Was Trump's Operation Warp Speed a Success?

A Personal Option for Health Care | Health Care Reimagined | Americans for Prosperity

The Supreme Court

Abortion Deserves Sober Debate, not a War of Unreason

This is a difficult moment for Roe v. Wade to have fallen.... Read More

Public Health

We Must End the Public Health Emergency Carefully

If Congress and the administration do not plan and work together, the end of the old emergency will only mark the beginning of a new emergency.... Read More

Health Care Reform

About That ObamaCare ‘Glitch’

The Affordable Care Act has faded into the political background since Republicans failed to repeal the entitlement in 2017, but ObamaCare still doesn't work as promised. The Biden Administration said this week that it will throw more money at one problem, and the result will be to hook more Americans on government subsidies. ... Read More